LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the ...
The North America liver disease treatment market accounted for $6,970 million in 2019, and is expected to reach $8,318 million by 2027, registering a CAGR of 5.2% from 2020 to 2027. Furthermore, liver ...